ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value of $0.50 per share for the 12-month period ending 2014-12-31, per its 10-K filed 2015-04-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue · last filed 2015-04-15
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2014-03-31 was $0.58.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for fiscal 2014 was $0.50.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 12 month |
|---|---|---|---|
| 2014-12-31 | $0.50 10-K · filed 2015-04-15 | ||
| 2014-09-30 | $0.22 10-Q/A · filed 2015-04-15 | ||
| 2014-03-31 | $0.58 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |